A powerful new tool for the separation of charged species

4 Feb 2018

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

Traditional separation technology in these fields provides particle size or molar mass distributions as the final result. It is clear, however, that particle and molecular charge plays a primary role in many applications such as protein aggregation, polymer flocculation, particle agglomeration and in pharmaceutical formulations in general.

A powerful new tool for the separation of charged species
Postnova's new EAF4 system.

The new Postnova EAF2000 instrument using EAF4 technology opens a completely new way to a significantly better understanding of these phenomena by allowing the particle size or molar mass distributions to be further differentiated and transformed into charge distributions. This allows identifying charge heterogeneities, which may be present within the different size and molar mass fractions and will quickly help to aid research or establish more efficient product development processes.

The EAF2000 instrument works by combining the principle of electrical and flow field-flow fractionation (FFF) in one experiment. In flow FFF the molecules and particles are gently separated in an open channel which avoids any interaction with column packing material keeping aggregation and structures intact. The electrical field, either positive or negative, can now be applied during this separation to differentiate between differently charged species of the same size or molecular weight.

The new Postnova EAF2000 technology is also designed in such a way that it allows the determination of the electrophoretic mobility (or zeta-potential) of the separated analytes under investigation. This is a key new tool, particularly for protein research as existing techniques for zeta-potential are limited by concentration and are simple batch techniques giving just an average value for all components in the solution. The new EAF2000 can determine the zeta-potential of each individually separated component such as protein monomer and dimer (or higher aggregates) or antibody monomer and fragments/aggregates.

Early successes with the technology have been found in applications as diverse as the separation of a positively charged pharmaceutical protein formulation, determination of the difference in zeta-potential of protein monomer and dimer and the differentiation of charge on polymer latex particles.

There is the first chance to see this technology in action on 6 March at the 2nd Postnova FFF Seminar at the company's UK headquarters in Malvern (UK). Following the popularity of the first Postnova first seminar, an informative program of talks from eminent guest speakers, plus presentations from Postnova scientists has been assembled.

The free 2018 seminar has been designed to advance the attendees knowledge of applications and techniques in nanoscale characterisation. The seminar will be particularly useful to those interested in using FFF, Size Exclusion Chromatography (SEC/GPC) and Light Scattering/Viscometry (MALS/DLS), as well as those interested in how these techniques may be useful in their research.

With limited attendee spaces available please register now for this free Seminar by contacting Postnova Analytics at info.uk@postnova.com.

Read More

Related news

Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Post-Brexit medicines - stuck in the UK?

Post-Brexit medicines - stuck in the UK?

30 Jul 2018

The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.

Read more 
Pharmacovigilance post-Brexit - simpler than previously thought?

Pharmacovigilance post-Brexit - simpler than previously thought?

24 Jul 2018

To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".

Read more 
South Korea's finished drug market growth driven by generics

South Korea's finished drug market growth driven by generics

16 Jul 2018

FDF launches at CPhI Korea as country set to become regional hub.

Read more 
Bosch to sell its packaging business

Bosch to sell its packaging business

4 Jul 2018

Packaging technology is not a core Bosch business.

Read more 
Ingredients to improve bioprocess manufacturing efficiency

Ingredients to improve bioprocess manufacturing efficiency

27 Jun 2018

Experts warn bio industry needs to do more to create a sustainable pipeline of talent.

Read more 
Internationalisation and regulatory reform driving growth and investment at CPhI China

Internationalisation and regulatory reform driving growth and investment at CPhI China

22 May 2018

2018 event prepares for surge in international attendees as MAH nears national rollout.

Read more 
Investing in blistering capabilities to boost flexibility

Investing in blistering capabilities to boost flexibility

16 May 2018

Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.

Read more 
Serialisation — looking for value-added opportunities

Serialisation — looking for value-added opportunities

15 May 2018

Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.

Read more 
Industry’s largest survey on serialization readiness throws up disparity

Industry’s largest survey on serialization readiness throws up disparity

30 Apr 2018

Global Drug Supply, Safety and Traceability Report reveals disparity in industry’s readiness to comply with track and trace regulations in the US and EU.

Read more